Skip to content

Etoricoxib Plus Paracetamol for Pain Management in Second Trimester Medical Abortion: A Double-Blind, Randomized, Placebo-controlled Trial

Etoricoxib Plus Paracetamol for Pain Management in Second Trimester Medical Abortion: A Double-Blind, Randomized, Placebo-controlled Trial

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
TCTR
Registry ID
TCTR20251224001
Enrollment
64
Registered
2025-12-24
Start date
2026-04-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain Pain

Interventions

One oral tablet of 90-mg etoricoxib plus a scheduled tablet of 500-mg paracetamol every 6 hours for a maximum of 2,000 mg per day,One oral starch-filled placebo tablet plus a scheduled tablet of 500-m
Experimental Drug,Placebo Comparator Drug
Etoricoxib plus paracetamol,Placebo plus paracetamol

Sponsors

Research Center, Faculty of Medicine, Ramathibodi Hospital, Mahidol University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Pregnant women aged more than or equal to 18 years old 2. Pregnant women who are fluent in Thai language

Exclusion criteria

Exclusion criteria: 1. Pregnant women with a history of drug hypersensitivity to aspirin, NSAIDs, etoricoxib, paracetamol, sulfamethoxazole, mifepristone, or misoprostol 2. Pregnant women with history of cardiovascular disease, ischemic heart disease, congestive heart failure, hypertension, cerebrovascular disease, peripheral arterial disease, active peptic ulcer disease, renal disease, or liver disease 3. Pregnant women who do not achieve complete abortion within 24 hours after administration of misoprostol 4. Pregnant women who are candidate for surgical intervention for second-trimester abortion such as inevitable abortion with active bleeding with unstable vital signs 5. Pregnant women who decline to participate 6. Pregnant women who have received any prohibited medication within 24 hours prior to initiation of misoprostol such as ibuprofen, naproxen, diclofenac, ketorolac, aspirin, celecoxib, parecoxib, morphine, tramadol, pethidine, methadone, gabapentin, pregabalin, ketamine, benzodiazepine, and additional paracetamol dose beyond paracetamol 500 mg orally every 6 hours 7. Pregnant women who have received any prohibited treatment within 24 hours prior to initiation of misoprostol such as paracervical block, peripheral nerve block, and spinal block

Design outcomes

Primary

MeasureTime frame
Pain score at expulsion Visual analog pain scale

Secondary

MeasureTime frame
Average pain score during abortion Visual analog pain scale,Number of additional opioid use during abortion total dose,Satisfaction score after abortion 5-point Likert scale,Vital signs during abortion and at expulsion Temperature, heart rate, blood pressure, respiratory rate

Countries

Thailand

Contacts

Public ContactWaranyu Lertrat

Department of Obstetrics and Gynecology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University

premwaranyu@gmail.com022011412

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026